2025-2026 Regular Session • US Congress Legislature
SB1095: Stop STALLING Act Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act
Legislative Summary
A bill to enable the Federal Trade Commission to deter filing of sham citizen petitions to cover an attempt to interfere with approval of a competing generic drug or biosimilar, to foster competition, and facilitate the efficient review of petitions filed in good faith to raise legitimate public health concerns, and for other purposes.
Demographic Impact
Overall analysis of equity impact
80% Positive
High ConfidenceView detailed demographic breakdown ↓Unlock Full Demographic Insights
Go beyond the overall score.
Gain a deeper understanding of this bill's potential impact across diverse communities, including detailed breakdowns by category and subgroup. Access to this granular analysis helps ensure equitable outcomes.
Enable full analysis features for your organization.
Contact Sales to Learn MoreOr email us directly at sales@legiequity.us.
Bill History
3/24/2025
Read twice and referred to the Committee on the Judiciary.
Senate
4/3/2025
Committee on the Judiciary. Ordered to be reported without amendment favorably.
Senate
4/10/2025
Committee on the Judiciary. Reported by Senator Grassley without amendment. Without written report.
Senate
4/10/2025
Placed on Senate Legislative Calendar under General Orders. Calendar No. 45.
Senate
Status Information
Current Status
Introduced(3/24/2025)
Chamber
Senate
Sponsors
Democrat: 5
Republican: 2
Primary Sponsor
Amy Klobuchar
Democrat